The acute lung injury refers to the clinical syndrome of acute respiratory failure because of acute inflammation, which causes disruption of the lung endothelial and epithelial barriers, adding substantial morbidity and mortality. The long-term quality of life is adversely affected. The research articles are majorly directed toward the identification of biomarkers involved within the inflammatory and coagulation cascades, for the early prediction of morbidity and mortality. Some of the clinical conditions with the development of acute lung injury are direct, such as pneumonia, pulmonary contusion, inhalational injury, indirect include sepsis, severe trauma, burns, head injury, and drug overdose.
Several high-quality studies have provided the estimates of the incidence, however, they vary by age, race/ethnicity influences, lifestyle factors, and several other environmental factors in each geography. The companies, in the initial studies, have targeted capillary endothelium, alveolar epithelium, and both in certain cases. The usual route of delivery in clinical trials is intravenous and intrathecal. Some of the pipeline approaches involve blockade of inflammatory responses, inhibition, and neutralization.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world, are provided, with data obtained from multiple sources. The report also includes a list of key sponsors, having pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation, by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation, by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Infographic Charts and Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence